MyMedR

Fulltext Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study

Doskaliuk B, Ravichandran N, Sen P, Day J, Joshi M, Nune A, et al.

Rheumatol Int, 2023 Sep;43(9):1651-1664.

PMID: 37351634 DOI: 10.1007/s00296-023-05345-y

Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb-June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35-58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2-7.0, p

Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study

Ali SS, R N, Sen P, Day J, Joshi M, Nune A, et al.

Rheumatology (Oxford), 2023 Sep 01;62(9):e263-e268.

PMID: 37004201 DOI: 10.1093/rheumatology/kead149

Flares of autoimmune rheumatic disease following COVID-19 infection: Observations from the COVAD study

Sandhu NK, Ravichandraan N, Nune A, Day J, Sen P, Nikiphorou E, et al.

Int J Rheum Dis, 2024 Jan;27(1):e14961.

PMID: 37969016 DOI: 10.1111/1756-185X.14961

Fulltext COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study

Andreoli L, Lini D, Schreiber K, Parodis I, Sen P, Ravichandran N, et al.

Rheumatology (Oxford), 2024 May 02;63(5):1341-1351.

PMID: 37505460 DOI: 10.1093/rheumatology/kead382

OBJECTIVES: We investigated coronavirus disease 2019 (COVID-19) vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) in the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study.

METHODS: Delayed-onset (>7 days) vaccine-related adverse events (AE), disease flares and AID-related treatment modifications were analysed upon diagnosis of AID vs healthy controls (HC) and the pregnancy/breastfeeding status at the time of at least one dose of vaccine.

RESULTS: Among the 9201 participants to the self-administered online survey, 6787 (73.8%) were women. Forty pregnant and 52 breastfeeding patients with AID were identified, of whom the majority had received at least one dose of COVID-19 vaccine (100% and 96.2%, respectively). AE were reported significantly more frequently in pregnant than in non-pregnant patients (overall AE 45% vs 26%, P = 0.01; minor AE 40% vs 25.9%, P = 0.03; major AE 17.5% vs 4.6%, P

Displaying all 4 publications